AlgometRx, Inc. Company Profile

Background

Overview

AlgometRx, Inc., founded in 2015, is a privately held biotechnology company headquartered in Washington, D.C. The company specializes in developing innovative medical devices aimed at objectively measuring pain, thereby transforming pain assessment and management practices. By integrating advanced technologies, AlgometRx seeks to provide healthcare professionals with precise tools to evaluate pain types and intensities, leading to more effective and personalized treatment strategies.

Key Strategic Focus

Core Objectives

• Objective Pain Measurement: Developing devices that offer real-time, objective assessments of pain to replace subjective self-reporting methods.

• Personalized Pain Management: Enabling tailored treatment plans based on accurate pain profiling.

Areas of Specialization

• Pediatric Pain Assessment: Focusing on non-verbal or young patients who cannot effectively communicate their pain levels.

• Neuropathic Pain Evaluation: Addressing complex pain conditions such as chemotherapy-induced peripheral neuropathy.

Key Technologies Utilized

• Pupillometry: Analyzing pupil responses to neuroselective stimulation to assess nociceptive activity.

• Proprietary Algorithms: Interpreting physiological data to determine pain type and intensity.

Primary Markets Targeted

• Healthcare Providers: Hospitals and clinics seeking advanced pain assessment tools.

• Pediatric Care Centers: Facilities specializing in children's health requiring objective pain measurement solutions.

Financials and Funding

Funding History

• Seed Round (April 2017): Raised $1,000,000 to support initial development efforts.

• Seed Round (November 2017): Secured an additional $50,000 to further product development.

• Grant (September 2022): Received $669,000 in grant funding to advance research initiatives.

Notable Investors

• National Cancer Institute: Provided funding to support research on pain assessment technologies.

• National Institute of Arthritis and Musculoskeletal Diseases: Invested in the development of objective pain measurement devices.

• Johnson & Johnson Innovation - JLABS: Offered accelerator support and residency at JLABS @ Washington, DC.

Utilization of Capital

Funds have been allocated towards research and development, clinical trials, and the commercialization of pain assessment devices.

Pipeline Development

Key Pipeline Candidates

• Nociometer: A device designed to objectively measure pain by analyzing pupil dilation in response to neuroselective stimulation.

Stages of Development

• Clinical Validation: Ongoing studies to validate the efficacy and accuracy of the Nociometer in various patient populations.

Target Conditions

• Vincristine-Induced Peripheral Neuropathy (VIPN): Assessing the device's capability to detect and monitor neuropathic pain in pediatric oncology patients.

• Systemic Lupus Erythematosus (SLE): Evaluating the technology's effectiveness in monitoring disease activity related to pain symptoms.

Anticipated Milestones

• Completion of Phase I SBIR Grants: Successfully executed two Phase I Small Business Innovation Research grants focused on lupus and VIPN applications.

• Preparation for Phase II Submissions: Planning to advance research into Phase II to further develop and commercialize the technology.

Technological Platform and Innovation

Proprietary Technologies

• Nociometer: A non-invasive, handheld device that captures real-time images of a patient’s pupillary response, applying proprietary algorithms to determine pain type and intensity.

Significant Scientific Methods

• Pupillometry: Utilizing infrared technology to measure pupil responses to specific stimuli, providing objective data on nociceptive processing.

• Neuroselective Stimulation: Employing targeted neurostimulation to elicit measurable physiological responses indicative of pain perception.

Leadership Team

Key Executives

• Dr. Julia Finkel: Founder and Chief Scientific Advisor. A pediatric anesthesiologist and pain medicine physician at Children's National Hospital, Dr. Finkel developed the foundational technology for AlgometRx, aiming to improve pain assessment in non-verbal pediatric patients.

• Kevin Jackson: Chief Operating Officer. Oversees the company's operations, bringing extensive experience in managing biotech ventures and guiding them through growth phases.

Competitor Profile

Market Insights and Dynamics

• Market Size: The global pain management devices market is experiencing significant growth, driven by increasing prevalence of chronic pain conditions and demand for non-invasive assessment tools.

• Growth Potential: Advancements in technology and a shift towards personalized medicine are expanding opportunities in objective pain measurement solutions.

Competitor Analysis

• STAT-Dx: Develops diagnostic systems integrating advanced technologies for rapid results, focusing on various medical conditions.

• BSP Medical: Specializes in non-invasive diagnostic tools, including devices for cardiac monitoring, with potential applications in pain assessment.

• Confer Health: Offers at-home diagnostic testing solutions, aiming to provide accessible and accurate health assessments.

Strategic Collaborations and Partnerships

Significant Collaborations

• Children’s National Hospital: AlgometRx is a spin-off from this institution, benefiting from ongoing research collaborations and clinical trial support.

• Johnson & Johnson Innovation - JLABS: Selected as a resident company, gaining access to resources, mentorship, and networking opportunities to accelerate development and commercialization efforts.

Operational Insights

Strategic Considerations

• Market Position: AlgometRx differentiates itself by offering objective, non-invasive pain assessment tools, addressing a critical gap in current pain management practices.

• Competitive Advantages: The company's proprietary technology, combined with strong clinical partnerships and a focus on pediatric applications, positions it uniquely in the market.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Product Commercialization: Advancing the Nociometer through regulatory approvals and bringing it to market.

• Expansion into New Indications: Exploring applications of the technology in other pain-related conditions and patient populations.

• Global Market Penetration: Establishing partnerships and distribution channels to reach international markets.

Current Strengths Positioning for Future Objectives

• Innovative Technology: The unique approach to pain assessment provides a strong foundation for future product development.

• Clinical Validation: Ongoing research and collaborations enhance credibility and facilitate adoption by healthcare providers.

• Strategic Partnerships: Alliances with reputable institutions and accelerators support growth and market entry strategies.

Contact Information

• Headquarters: Washington, D.C., United States

Note: Specific contact details such as address, phone number, and email are not provided in this profile.